Ferbeyre G
Université de Montréal, Département de Biochimie, Canada.
Leukemia. 2002 Oct;16(10):1918-26. doi: 10.1038/sj.leu.2402722.
PML is the most frequent fusion partner of the RARalpha in the specific translocations associated with acute promyelocytic leukemia (APL). Models to explain the origin of this leukemia propose a block in cell differentiation due to aberrant repression of retinoic acid responsive genes and/or disruption of the function of the PML-containing nuclear bodies. Recently, PML has been identified as a regulator of replicative senescence and the premature senescence that occurs in response to oncogenic ras. This review discusses the idea that senescence is a general tumor suppressor mechanism related to terminal differentiation and disrupted during the establishment of APL and other cancers. According to this idea the PML-RARalpha fusion protein promotes leukemogenesis not only through repression of retinoic acid responsive genes, but also by way of interfering with several tumor suppressor proteins that cooperate to establish senescence. Retinoids and other drugs effective against APL do so by re-establishment of the senescence program, which also includes features of cell differentiation.
在与急性早幼粒细胞白血病(APL)相关的特定易位中,早幼粒细胞白血病蛋白(PML)是维甲酸受体α(RARα)最常见的融合伙伴。解释这种白血病起源的模型提出,由于维甲酸反应基因的异常抑制和/或含PML核体功能的破坏,细胞分化受阻。最近,PML已被确定为复制性衰老和因致癌性ras而发生的过早衰老的调节因子。本综述讨论了衰老作为一种与终末分化相关的一般肿瘤抑制机制,在APL和其他癌症发生过程中被破坏的观点。根据这一观点,PML-RARα融合蛋白不仅通过抑制维甲酸反应基因促进白血病发生,还通过干扰几种协同建立衰老的肿瘤抑制蛋白来实现。类维生素A和其他对APL有效的药物通过重新建立衰老程序来发挥作用,该程序还包括细胞分化的特征。